New pill tested for brain conditions linked to down syndrome and Alzheimer's
NCT ID NCT06206824
Summary
This is the first study in people to test the safety of an experimental oral drug called Leucettinib-21. It will first be given to healthy volunteers to check for side effects and how the body processes it. Later, a single dose will be given to a small group of men with Down syndrome or Alzheimer's disease to see how they tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eurofins Optimed
RECRUITINGGières, 38610, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.